3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
61
Leucovorin
56
Oxaliplatin
51
Capecitabine
42
Irinotecan
29
Bevacizumab
21
Radiotherapy
17
Cetuximab
12
Folfox protocol
11
Chemoradiotherapy
11
Neoadjuvant Therapy
10
Chemotherapy, Adjuvant
9
Surgical Procedures, Operative
6
Drug Therapy
6
XELOX
5
Panitumumab
4
Laparoscopy
4
FOLFOXIRI protocol
4
Transanal Endoscopic Microsurgery
3
Radiation
3
Octreotide
3
IFL protocol
3
Floxuridine
3
Diathermy
3
Celecoxib
3
vatalanib
2
spartalizumab
2
Trinitrotoluene
2
Tegafur
2
Semaxinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Rectal Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled